Euroopa Liit - leedu - EMA (European Medicines Agency)

accord healthcare s.l.u. - repaglinidas - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - repaglinidas yra skiriamas pacientams, sergantiems 2 tipo cukriniu diabetu (ne-nuo insulino nepriklausomu cukriniu diabetu (niddm)), kurių hiperglikemija gali nebe būti gerai kontroliuojama dietinėmis dieta, svorio sumažinimo ir fizinio. gydymas turi būti pradėtas kaip papildoma priemonė kartu su dieta ir fiziniais pratimais sumažinti kraujo gliukozės dėl valgiai.

Euroopa Liit - leedu - EMA (European Medicines Agency)

eli lilly nederland b.v. - dulaglutidas - cukrinis diabetas, 2 tipas - drugs used in diabetes, blood glucose lowering drugs, excl. insulins - trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. už studijų rezultatus, atsižvelgiant į derinius, poveikis glycaemic kontroliuoti širdies ir kraujagyslių įvykių, gyventojų, studijavo, žr. skirsnius 4. 4, 4. 5 ir 5.

Euroopa Liit - leedu - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Euroopa Liit - leedu - EMA (European Medicines Agency)

krka, d.d., novo mesto - repaglinidas - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - repaglinidas yra skiriamas pacientams, sergantiems 2 tipo cukriniu diabetu (ne-nuo insulino nepriklausomu cukriniu diabetu (niddm)), kurių hiperglikemija gali nebe būti gerai kontroliuojama dietinėmis dieta, svorio sumažinimo ir fizinio. gydymas turi būti pradėtas kaip papildoma priemonė kartu su dieta ir fiziniais pratimais sumažinti kraujo gliukozės dėl valgiai.

Euroopa Liit - leedu - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - linagliptinas - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - trajenta yra nurodyta, gydant 2 tipo cukriniu diabetu, siekiant pagerinti glycaemic kontrolės suaugusiems:kaip monotherapyin pacientai nepakankamai kontroliuojama dieta ir mankšta vieni, ir kam metforminas yra netinkamas dėl netolerancijos, arba kontraindikuotinas dėl inkstų pažeidimas. kaip derinys therapyin kartu su metforminas, kai dieta ir mankšta plius metforminas vien nesuteikia pakankamos kontrolės glycaemic. kartu su sulfonilkarbamido dariniai ir metforminas, kai dieta ir mankšta plus dual terapija su šių vaistų nesuteikia pakankamos kontrolės glycaemic. kartu su insulino su arba be metforminas, kai šis režimas vien su dieta ir mankšta, neužtikrina adekvačios glycaemic kontrolės.

Euroopa Liit - leedu - EMA (European Medicines Agency)

takeda pharma a/s - alogliptinas - cukrinis diabetas, 2 tipas - drugs used in diabetes, dipeptidyl peptidase 4 (dpp-4) inhibitors - vipidia yra suaugusių 18 metų amžiaus ir vyresniems sergantiems 2 tipo cukriniu diabetu pagerinti glikemijos kontrolę kartu su kitais gliukozės kiekį mažinantis vaistiniais preparatais, įskaitant insuliną, kai pastarieji kartu su dieta ir fiziniais pratimais, kurie nesuteikia pakankamai gliukozės kiekio kraujyje kontrolę (žr. 4. 4, 4. 5 ir 5. 1, jei yra duomenų apie skirtingus derinius).

Euroopa Liit - leedu - EMA (European Medicines Agency)

novartis europharm limited - vildagliptinas - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ir 5. 1, jei yra duomenų apie skirtingus derinius).

Euroopa Liit - leedu - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Euroopa Liit - leedu - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Euroopa Liit - leedu - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - pioglitazono hidrochloridas - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - pioglitazone yra nurodyta, gydant 2 tipo cukriniu diabetu:kaip monotherapy:pacientams (ypač antsvorio pacientams) nepakankamai kontroliuojama dieta ir mankšta kam metforminas netinka dėl kontraindikacijų ar netolerancija;kaip dual žodžiu terapija kartu su:metforminas, pacientams (ypač antsvorio pacientams) nepakankamai glycaemic kontrolės nepaisant maksimaliai toleruojama dozė monotherapy su metforminas;a sulfonilkarbamido dariniai, tik pacientams, kurie rodo, nepakantumas metforminas arba kuriam metforminas yra kontraindikuotinas, nepakankamai glycaemic kontrolės nepaisant maksimaliai toleruojama dozė monotherapy su sulfonilkarbamido dariniai;kaip trijų burnos terapija kartu su:metforminas ir sulfonilkarbamido dariniai, pacientams (ypač antsvorio pacientams) nepakankamai glycaemic kontrolės nepaisant dual žodžiu terapija. pioglitazone taip pat nurodė, kartu su insulinui, 2 tipo cukriniu diabetu sergantiems pacientams su nepakankama glycaemic kontroliuoti insulino kam metforminas netinka dėl kontraindikacijų ar netolerancija.